Charlotte L. Zuur

Department Of Otolaryngology And Head And Neck Surgery
Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 68 publications

A Prospective Multicenter Observational Study Investigating the Concordance Between Patient-Reported Hearing Loss and Commonly Used Ototoxicity Grading Systems in Patients Treated with Platinum-Based Chemotherapy.

A Prospective Multicenter Observational Study Investigating the Concordance Between Patient-Reported Hearing Loss and Commonly Used Ototoxicity Grading Systems in Patients Treated with Platinum-Based Chemotherapy.

Journal: The Annals of otology, rhinology, and laryngology
Published: January 18, 2026

Transtympanic sodium thiosulphate to prevent cisplatin-related hearing loss: a protocol for randomised controlled multicentre phase III trial, the SOUND trial.

Transtympanic sodium thiosulphate to prevent cisplatin-related hearing loss: a protocol for randomised controlled multicentre phase III trial, the SOUND trial.

Journal: BMJ open
Published: December 03, 2025

Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

Journal: Nature medicine
Published: July 10, 2025

Surgeon's perceptions on 3D visualization methods in parotid gland tumor surgery.

Surgeon's perceptions on 3D visualization methods in parotid gland tumor surgery.

Journal: Frontiers in oncology
Published: June 27, 2025

[18F]FDG-PET/CT's change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial.

[18F]FDG-PET/CT's change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial.

Journal: European journal of nuclear medicine and molecular imaging
Published: February 06, 2025

Comparison of cisplatin-induced hearing loss in different durations of infusion and volume of hydration schedules in head and neck squamous cell carcinoma patients treated with cisplatin-based chemoradiation.

Comparison of cisplatin-induced hearing loss in different durations of infusion and volume of hydration schedules in head and neck squamous cell carcinoma patients treated with cisplatin-based chemoradiation.

Journal: Oral oncology
Published: January 08, 2025

Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial.

Journal: Nature medicine
Published: December 09, 2024

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

Journal: The New England journal of medicine
Published: June 03, 2024

Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer.

Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer.

Journal: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
Published: April 10, 2024

Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma.

Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma.

Journal: JCI insight
Published: February 02, 2024

The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy.

The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy.

Journal: Cancer medicine
Published: January 15, 2024

The association between skeletal muscle mass and sensorineural hearing loss upon cisplatin-based chemoradiotherapy in patients with head and neck squamous cell carcinoma.

The association between skeletal muscle mass and sensorineural hearing loss upon cisplatin-based chemoradiotherapy in patients with head and neck squamous cell carcinoma.

Journal: Head & neck
Published: December 14, 2023
Showing 1-12 of 68

Last Updated: 09/26/2026